Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

• Published in: The Journal of clinical investigation 2015-09, Vol.125 (9), p.3377-3383
• Main Authors: Buchbinder, Elizabeth, Hodi, F Stephen
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antigen receptors, T cell; Antigens; Biomedical research; Cancer; Care and treatment; Cell Cycle Checkpoints - drug effects; Cell Cycle Checkpoints - immunology; Cell growth; CTLA-4 Antigen - antagonists & inhibitors; CTLA-4 Antigen - immunology; Cytotoxicity; Dendritic cells; Genetic aspects; Health aspects; Humans; Immune response; Immune system; Immunoglobulins; Immunotherapy; Lymphocytes; Medical prognosis; Melanoma; Melanoma - immunology; Melanoma - pathology; Melanoma - therapy; Metastasis; Neoplasm Metastasis; Receptors; Review Series; T cell receptors; T cells; T-Lymphocytes, Cytotoxic - immunology; T-Lymphocytes, Cytotoxic - pathology; Tumors
• ISSN: 0021-9738; 1558-8238
• DOI: 10.1172/JCI80012

The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation by costimulatory signals. Fully human monoclonal antibodies targeting CTLA-4 have been shown to increase T cell function and antitumor responses in patients with advanced metastatic melanoma. Responses observed with such immune checkpoint therapy can follow a different pattern from that seen with cytotoxic chemotherapy or targeted therapy and may continue after therapy is discontinued. In addition, the toxicities that are associated with anti-CTLA-4 therapy may differ from those of conventional therapies and consist of inflammatory events in parts of the body that do not contain cancerous cells. Early recognition of these inflammatory events and intervention is important, and the identification of predictive biomarkers continues to be an unfulfilled need in the field of immunotherapy. Combinatorial approaches with targeted therapies, radiation therapy, chemotherapy, or other immune checkpoint agonists/antagonists have the potential to increase the efficacy of CTLA-4 blockade.